← All trials
NCT00004934
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 1999
- Primary completion
- —
- Completion date
- May 1, 2003
- First posted
- —
- Last posted
- —
- Enrollment
- —
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- Nordic Society for Gynaecologic OncologyLead sponsor
- Katholieke Universiteit LeuvenStudy chair
- European Organisation for Research and Treatment of CancerCollaborator
- University of CalgaryStudy chair
- Canadian Cancer Trials GroupCollaborator
- University of OsloStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.